Clinical trials: Granulocyte Colony-Stimulating Factor
Lymphoma
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
Primary Objectives: 1. To determine the efficacy of in vivo purging achieved by rituximab in the two groups. 2. To determine the number of apheresis procedures, total stem cell yield/kg patient body weight and the toxicity…
- Trial name
- NCT00499343
- Testing
- Etoposide, G-CSF, GM-CSF
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
The goal of this clinical research study is to learn if treatment with two types of chemotherapy combinations can help to control peripheral T-cell lymphoma.
- Trial name
- NCT00290433
- Testing
- Cyclophosphamide, Mesna, Vincristine
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of liposome-encapsulated daunorubicin-cytarabine when given with fludarabine phosphate, cytarabine, and filgrastim and to see how well they work in treating younger…
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Trial name
- NCT02642965
- Testing
- Cytarabine, Filgrastim, Fludarabine Phosphate
- Where
- 73 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- Children's Oncology Group
Hematologic Diseases, Hematologic Malignancies
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
The major purpose of this study is to evaluate the curative potential of white cell growth hormone (G-CSF)-stimulated bone marrow cells in allogeneic bone marrow transplants.
- Trial name
- NCT00231309
- Testing
- Granulocyte Colony Stimulating Factor
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Emory University
Melanoma
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
The objective of this study is to evaluate the efficacy and safety of treatment with talimogene laherparepvec compared to subcutaneously administered GM-CSF in patients with unresectable Stage IIIb, IIIc and Stage IV melanoma.
- Trial name
- NCT00769704
- Testing
- Talimogene laherparepvec, GM-CSF
- Where
- 83 sites in United States, Canada and 2 more
- Volunteers
- 437 people
- Sponsor
- BioVex Limited
Hereditary Pulmonary Alveolar Proteinosis
Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
The purpose of this study is to evaluate the therapeutic efficacy of inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (PAP) due to partial dysfunction of the GM-CSF receptor.
- Trial name
- FAMPAP (NCT01511068)
- Testing
- Leukine
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Neutropenia, Breast Cancer
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
A Phase I, dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of F-627 in female breast cancer patients who received up to 4 cycles of Epirubicin and Cyclophosphamide.
- Trial name
- NCT02527746
- Testing
- F-627, EC regimen
- Volunteers
- 18 people
- Sponsor
- EVIVE Biotechnology
Primary Ovarian Insufficiency, Premature Ovarian Failure
The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
The goal of this pilot study is to improve ovarian reserve markers in patients with premature ovarian insufficiency. The main question it aims to answer is: Will treatment with G-CSF allow improvement in markers of ovarian…
- Trial name
- NCT06117982
- Testing
- Neupogen
- Where
- Canada
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Trio Fertility
Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Diffuse large B-cell lymphoma is a most prevalent non-Hodgkin's lymphoma. Recently the clinical results have been improved with new drugs and new modalities such as cyclophosphamide, doxorubicin, vincristine, and prednisone…
- Trial name
- NCT00379574
- Testing
- Bortezomib, Cyclophosphamide, Doxorubicin
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Asan Medical Center
Dystrophic Epidermolysis Bullosa
Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
This is a feasibility study to see if Granulocyte Colony Stimulating Factor (GCSF) is effective as a treatment of Dystrophic Epidermolysis Bullosa (EB). Patients will receive one course of treatment with the study drug.
- Trial name
- NCT01538862
- Testing
- Granulocyte Colony Stimulating Factor (GCSF)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt University Medical Center
Healthy
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers
This 12-day study will test whether the combination of G-CSF (granulocyte-colony stimulating factor) and AMD3100 (Mozobil) is more efficient in mobilizing stem cells for collection than the use of G-CSF alone.
- Trial name
- NCT00082329
- Testing
- AMD 3100 (Mozobil plerixafor), Granulocyte colony-stimulating factor (G-CSF)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Ovarian Cancer, Primary Peritoneal Cancer
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
This research study is evaluating the effect (good and bad) of a dendritic cell/tumor fusion vaccine in combination with the laboratory made agents GM-CSF and imiquimod on the participants immune system.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00799110
- Testing
- GM-CSF, Dendritic Cell/Tumor Fusion Vaccine, imiquimod
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Beth Israel Deaconess Medical Center
Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and the best dose of pomalidomide when given together with dexamethasone and filgrastim-sndz and to see how well they work in treating patients with multiple myeloma that has…
- Conditions
- Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01946152
- Testing
- Dexamethasone, Filgrastim-sndz, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Postmenopausal Symptoms
A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women
The purpose of this study is to assess the efficacy and safety of repeated administration of G-CSF for the treatment of hot flashes and vasomotor symptoms in women with naturally-occurring or surgically induced menopause.
- Trial name
- NCT03640754
- Testing
- G-CSF
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- MenoGeniX, Inc.
Multiple Myeloma
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L
The purpose of this study is to compare the effects, good and bad, of two ways to treat patients with standard-risk symptomatic multiple myeloma.
- Trial name
- NCT00807599
- Testing
- Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
- Trial name
- GENESIS (NCT03246529)
- Testing
- BL-8040 1.25 mg/kg + G-CSF
- Where
- 18 sites in United States, Germany and 3 more
- Volunteers
- 180 people
- Sponsor
- BioLineRx, Ltd.
Prostatic Neoplasms
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
The purpose of this study is to evaluate the effect of the combination of mitoxantrone and granulocyte-macrophage colony stimulating factor (GM-CSF) on progression-free survival (PFS) and overall survival (OS), in patients with…
- Trial name
- NCT00477087
- Testing
- Mitoxantrone, GM-CSF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Infertility
Efficacy Study of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) for Use in Human IVF
This study is to assess whether addition of 2 ng/ml GM-CSF into a specific culture medium will increase the chance of a pregnancy after in vitro fertilisation.
- Trial name
- GM-CSF (NCT00565747)
- Testing
- Test culture, Control culture
- Where
- 14 sites in Denmark, Sweden
- Volunteers
- 1,332 people
- Sponsor
- Origio A/S
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II clinical trial is studying the how well veliparib, topotecan hydrochloride, and filgrastim or pegfilgrastim work in treating patients with persistent or recurrent cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT01266447
- Testing
- Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim
- Where
- 78 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Lymphoma, Non-Hodgkin
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
This study will compare the results of stem cell mobilization using drugs called filgrastim (Neupogen) and plerixafor with the results of stem cell mobilization using drugs called XM02 filgrastim (Granix) and plerixafor.
- Trial name
- NCT02098109
- Testing
- XM02 Filgrastim, Filgrastim, Apheresis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Washington University School of Medicine